The landscape of HLA mediated variation in health and immunity

HLA 介导的健康和免疫力变化

基本信息

项目摘要

Project Summary The Human Leukocyte Antigen (HLA) region on human chromosome 6p21 is the most medically important region of the human genome. More than 100 infectious, autoimmune and pharmacological disease phenotypes and cancers are associated with genetic variation of HLA. Nevertheless, despite nearly a half-century of study investigating HLA and disease association, outstanding questions remain regarding the full extent of HLA mediated impact on human health and disease. A major limitation to these studies, lack of sufficient sample size for discovery and replication, can be attributed to the complex nature of the HLA region such that it is often impractical to undertake association studies in very large cohorts. To date, nearly all large-scale studies examining HLA variation in human health have relied on statistical imputation of HLA alleles from SNP (single nucleotide polymorphism) data, rather than direct genotyping of these loci. Here, we propose to exploit pre-existing, high-quality HLA genotyping data collected by the National Marrow Donor Program in order to examine the impact of HLA variation in human health and immunity at unprecedented scale. We will collect self-reported health histories from a sample of greater than 100,000 individuals, allowing examination of genotype-phenotype associations with high-resolution genotypes. Further, we will examine the relationship between HLA variation and antibody response to human cytomegalovirus (CMV) in more than 1,000,000 individuals. To provide context to the association studies, we will examine the relationship between HLA variation and antigenic targets of antibodies in more than 1000 healthy individuals. In Specific Aim 1 we will build a very large dataset collected through the National Marrow Donor Program (NMDP) to identify potential HLA associations across numerous diseases and phenotypes in a Phenome Wide Association study (PheWAS). Phenotype information for PheWAS analysis will be obtained from self-report survey data for approximately 130 conditions, diseases and traits from subjects with HLA genotyping collected by NMDP. In Specific Aim 2 we will determine the antigen specificity of antibodies in serum samples from healthy subjects, stratified by HLA genotype. We will utilize a programmable phage display assay, comprised of 744,000 peptides tiled across the human proteome, representing the entire human peptidome. Additionally, we will screen against the phage display for the virome (480,000 peptides) for specificity for viral antigens, and test binding of these antigens to HLA molecules. We will examine serum samples from over 1000 healthy donors. In Specific Aim 3, we will specifically address serostatus with respect to human cytomegalovirus (CMV) in a sample of over a million individuals. CMV is ubiquitous in all human populations and infection can have profound effects on the immune system. This analysis will provide the first large-scale examination of the association of HLA variation with CMV serostatus. Across multiple elements of human health and immunity, the key feature of this study is the extraordinarily large sample size projected for each of our aims, made possible through our leveraging of existing high-resolution HLA genotyping data. In doing so, we will extend our understanding of the effect of these important immune loci in human health across a wide range of conditions, across multiple ancestries reflective of the United States population.
项目摘要 人类染色体6p21上的人类白细胞抗原(人类白细胞抗原)区域是人类染色体中最重要的医学区域。 人类基因组。100多种传染病、自身免疫性和药物性疾病表型与癌症有关 与人类白细胞抗原的遗传变异有关。然而,尽管对人类白细胞抗原和疾病进行了近半个世纪的研究 尽管如此,关于人类白细胞抗原对人类健康和疾病的全面影响,仍然存在悬而未决的问题。 这些研究的一个主要限制是缺乏足够的样本量来发现和复制,这可以归因于 人类白细胞抗原区域的复杂性使得在非常大的队列中进行关联研究往往是不切实际的。至 迄今为止,几乎所有检测人类健康中人类白细胞抗原变异的大规模研究都依赖于人类白细胞抗原的统计归因 来自SNP(单核苷酸多态)数据的等位基因,而不是这些基因座的直接基因分型。在此,我们建议 利用国家骨髓捐赠者计划收集的预先存在的高质量的人类白细胞抗原基因分型数据,以便 以前所未有的规模研究人类白细胞抗原变异对人类健康和免疫的影响。我们将收集自我报告 超过100,000人的样本的健康史,允许检查基因-表型 与高分辨率基因型别的关联。进一步,我们将研究人类白细胞抗原变异与抗体之间的关系。 100,000多人对人类巨细胞病毒(CMV)的反应。为关联提供上下文 研究中,我们将检查1000多个抗体的抗原靶标与人类白细胞抗原变异的关系 健康的个体。在具体目标1中,我们将建立一个通过国家骨髓捐赠者收集的非常大的数据集 项目(NMDP),以确定在广泛的表型组中跨多种疾病和表型的潜在的人类白细胞抗原关联 联合研究(Phewas)。Phewas分析的表型信息将从自我报告调查数据中获得 来自NMDP收集的大约130种条件、疾病和特征的人类白细胞抗原基因分型受试者。具体而言 目的2我们将测定健康受试者血清中抗体的抗原特异性,按人类白细胞抗原(Has)进行分层。 基因分型。我们将利用一种可编程的噬菌体展示试验,它由744,000个横跨人体的多肽组成 蛋白质组,代表整个人类多肽组。此外,我们将针对病毒的噬菌体展示进行筛选 (480,000个多肽)用于病毒抗原的特异性,并测试这些抗原与人类白细胞抗原分子的结合。我们将研究 来自1000多名健康捐赠者的血清样本。在具体目标3中,我们将具体解决与以下方面有关的血清状态 人类巨细胞病毒(CMV)在100多万人的样本中。巨细胞病毒在所有人类群体中普遍存在, 感染会对免疫系统产生深远的影响。这一分析将提供第一次大规模的 巨细胞病毒血清状态与人类白细胞抗原变异的关系在人类健康和免疫力的多个要素中,关键 这项研究的特点是为我们的每个目标预测了非常大的样本量,通过我们的 利用现有的高分辨率的人类白细胞抗原基因分型数据。在这样做的过程中,我们将扩大对 这些重要的免疫位点在人类健康的广泛条件下,跨多个祖先反映了 美国人口。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JILL Allison HOLLENBACH其他文献

JILL Allison HOLLENBACH的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JILL Allison HOLLENBACH', 18)}}的其他基金

Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course
自然杀伤细胞多样性在多发性硬化症风险和疾病过程中的作用
  • 批准号:
    10707310
  • 财政年份:
    2022
  • 资助金额:
    $ 75.01万
  • 项目类别:
Role of Natural Killer Cell Diversity in Multiple Sclerosis Risk and Disease Course
自然杀伤细胞多样性在多发性硬化症风险和疾病过程中的作用
  • 批准号:
    10586853
  • 财政年份:
    2022
  • 资助金额:
    $ 75.01万
  • 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
  • 批准号:
    10655366
  • 财政年份:
    2021
  • 资助金额:
    $ 75.01万
  • 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
  • 批准号:
    10450114
  • 财政年份:
    2021
  • 资助金额:
    $ 75.01万
  • 项目类别:
The landscape of HLA mediated variation in health and immunity
HLA 介导的健康和免疫力变化
  • 批准号:
    10402884
  • 财政年份:
    2021
  • 资助金额:
    $ 75.01万
  • 项目类别:
MHC Variation in Host Response to SARS-CoV2 and COVID-19 Outcomes
宿主对 SARS-CoV2 和 COVID-19 结果反应的 MHC 变化
  • 批准号:
    10297642
  • 财政年份:
    2021
  • 资助金额:
    $ 75.01万
  • 项目类别:
The landscape of HLA mediated variation in health and immunity
HLA 介导的健康和免疫力变化
  • 批准号:
    10609519
  • 财政年份:
    2021
  • 资助金额:
    $ 75.01万
  • 项目类别:
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data
当前和未来一代免疫基因组数据的集成交换和存储
  • 批准号:
    10442226
  • 财政年份:
    2017
  • 资助金额:
    $ 75.01万
  • 项目类别:
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic Data
当前和未来一代免疫基因组数据的集成交换和存储
  • 批准号:
    10553161
  • 财政年份:
    2017
  • 资助金额:
    $ 75.01万
  • 项目类别:
MHC variation at high resolution in multiple sclerosis
多发性硬化症中 MHC 高分辨率变异
  • 批准号:
    9353595
  • 财政年份:
    2017
  • 资助金额:
    $ 75.01万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 75.01万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了